Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 1 15Phase 3 8Phase 4 4Phase 1/2 3Phase 2/3 2

Status

Unknown 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 17Breast 15Genitourinary 11Other hematologic neoplasm 9Lymphoid 9Sarcoma 7CNS 7Head & Neck 4Dermatologic 4Tumor-Agnostic 3Thoracic 3Myeloid 3Endocrine 3Plasma cell 2Other solid neoplasm 2NET 2Gynecologic 1

Conditions

Neuroendocrine Tumors 2Metatropic dwarfism 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Everolimus × Endocrine × Clear all
NCT02205515 2022-08-19

EBRT

Sunnybrook Health Sciences Centre

Phase 1/2 Completed
17 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

King Faisal Specialist Hospital & Research Center

Phase 1/2 Unknown
30 enrolled
EndocrineNET

Metatropic dwarfism, Neuroendocrine Tumors

NCT01175096 2010-08-04

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Guangdong Provincial People's Hospital

Phase 1/2 Unknown
20 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡